[PDF][PDF] How β3‐adrenoceptor‐selective is mirabegron?
MC Michel - British journal of pharmacology, 2016 - researchgate.net
British journal of pharmacology, 2016•researchgate.net
Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G et al.(2012).
Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two
phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Clin Ther 34: 2144–2160.
Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two
phase I, randomized, multiple-dose studies in healthy young and elderly men and women.
Clin Ther 34: 2144–2160.
Krauwinkel W, van Dijk J, Schaddelee M, Eltink C, Meijer J, Strabach G et al.(2012). Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women. Clin Ther 34: 2144–2160.
researchgate.net
